The human antiviral factor TRIM11 is under the regulation of HIV-1 Vpr

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Yuan, Ting ^a   Yao, Weitong ^a   Huang, Fang ^a   Sun, Binlian ^a   Yang, Rongge ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; PROTEASOME; PROTEIN TRIM11; RING FINGER PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPR PROTEIN; VPRBP PROTEIN; LUCIFERASE; PRIMER DNA; SMALL INTERFERING RNA; TRIM11 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELETION MUTANT; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION; GENE VECTOR; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; VIRUS ENTRY;

DNA PRIMERS; GENETIC VECTORS; HEK293 CELLS; HIV LONG TERMINAL REPEAT; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; UBIQUITIN-PROTEIN LIGASES; VIRUS INTERNALIZATION; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84905671019     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104269     Document Type: Article

References (50)

1. Nielsen MH, Pedersen FS, Kjems J (2005) Molecular strategies to inhibit HIV-1 replication. Retrovirology 2.
2. Yan N, Chen ZJJ (2012) Intrinsic antiviral immunity. Nat Immunol 13: 214-222.
3. Ndung'u T (2011) TRIM E3 ligases in HIV infection Can these intrinsic immunity factors be harnessed for novel antiviral strategies? Virulence 2: 360-366.
4. Ozato K, Shin DM, Chang TH, Morse HC (2008) TRIM family proteins and their emerging roles in innate immunity. Nature Reviews Immunology 8: 849-860.
5. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, et al. (2005) Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 79: 3930-3937. (Pubitemid 40388333)
6. Berthoux L, Sebastian S, Sayah DM, Luban J (2005) Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol 79: 7883-7888. (Pubitemid 40756824)
7. Colin L, Van Lint C (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6: 111.
8. Allouch A, Di Primio C, Alpi E, Lusic M, Arosio D, et al. (2011) The TRIM family protein KAP1 inhibits HIV-1 integration. Cell Host Microbe 9: 484-495.
9. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W (2008) TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4: e16.
10. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ (2000) A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Research 28: 663-668. (Pubitemid 30068248)
11. Rohr O, Marban C, Aunis D, Schaeffer E (2003) Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 74: 736-749. (Pubitemid 38040350)
12. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, et al. (1993) A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. Embo Journal 12: 3551-3558. (Pubitemid 23256442)
13. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, et al. (2011) TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol 85: 5183-5196.
14. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, et al. (2013) TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol 87: 257-272.
15. Sharifi HJ, Furuya AM, de Noronha CM (2012) The role of HIV-1 Vpr in promoting the infection of nondividing cells and in cell cycle arrest. Curr Opin HIV AIDS 7: 187-194.
16. Zhao RY, Li G, Bukrinsky MI (2011) Vpr-host interactions during HIV-1 viral life cycle. J Neuroimmune Pharmacol 6: 216-229.
17. Kogan M, Rappaport J (2011) HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 8: 25.
18. Guenzel CA, Herate C, Benichou S (2014) HIV-1 Vpr-a still "enigmatic multitasker". Front Microbiol 5: 127.
19. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA (1999) Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem 274: 9083-9091. (Pubitemid 29164715)
20. Lyonnais S, Gorelick RJ, Heniche-Boukhalfa F, Bouaziz S, Parissi V, et al. (2013) A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA. Virus Research 171: 287-303.
21. Nermut MV, Fassati A (2003) Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J Virol 77: 8196-8206. (Pubitemid 36871447)
22. Guenzel CA, Herate C, Le Rouzic E, Maidou-Peindara P, Sadler HA, et al. (2012) Recruitment of the nuclear form of uracil DNA glycosylase into virus particles participates in the full infectivity of HIV-1. J Virol 86: 2533-2544.
23. Mansky LM, Preveral S, Selig L, Benarous R, Benichou S (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J Virol 74: 7039-7047. (Pubitemid 30470687)
24. Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, et al. (2004) Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol 24: 9286-9294. (Pubitemid 39391667)
25. Yang B, Chen K, Zhang C, Huang S, Zhang H (2007) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J Biol Chem 282: 11667-11675. (Pubitemid 47100658)
26. Kaiser SM, Emerman M (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol 80: 875-882. (Pubitemid 43062899)
27. Wen X, Casey Klockow L, Nekorchuk M, Sharifi HJ, de Noronha CM (2012) The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover. PLoS One 7: e30939.
28. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 79: 10978-10987. (Pubitemid 41170639)
29. Maudet C, Sourisce A, Dragin L, Lahouassa H, Rain JC, et al. (2013) HIV-1 Vpr induces the degradation of ZIP and sZIP, adaptors of the NuRD chromatin remodeling complex, by hijacking DCAF1/VprBP. PLoS One 8: e77320.
30. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo Journal 23: 2451-2458. (Pubitemid 38954852)
31. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 245-252. (Pubitemid 351494713)
32. Hrecka K, Hao CL, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-U137.
33. Gong J, Shen XH, Qiu H, Chen C, Yang RG (2011) Rhesus monkey TRIM5alpha represses HIV-1 LTR promoter activity by negatively regulating TAK1/TAB1/TAB2/TAB3-complex-mediated NF-kappaB activation. Arch Virol 156: 1997-2006.
34. Brussel A, Sonigo P (2003) Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol 77: 10119-10124. (Pubitemid 37122094)
35. Terreni M, Valentini P, Liverani V, Gutierrez MI, Di Primio C, et al. (2010) GCN5-dependent acetylation of HIV-1 integrase enhances viral integration. Retrovirology 7.
36. Luznik L, Kraus G, Guatelli J, Richman D, Wong-Staal F (1995) Tatin-dependent replication of human immunodeficiency viruses. J Clin Invest 95: 328-332.
37. Niikura T, Hashimoto Y, Tajima H, Ishizaka M, Yamagishi Y, et al. (2003) A tripartite motif protein TRIM11 binds and destabilizes Humanin, a neuroprotective peptide against Alzheimer's disease-relevant insults. Eur J Neurosci 17: 1150-1158. (Pubitemid 36459769)
38. Ishikawa H, Tachikawa H, Miura Y, Takahashi N (2006) TRIM11 binds to and destabilizes a key component of the activator-mediated cofactor complex (ARC105) through the ubiquitin-proteasome system. Febs Letters 580: 4784-4792. (Pubitemid 44286834)
39. Tuoc TC, Stoykova A (2008) Trim11 modulates the function of neurogenic transcription factor Pax6 through ubiquitin-proteosome system. Genes & Development 22: 1972-1986. (Pubitemid 352008644)
40. Parodi S, Di Zanni E, Di Lascio S, Bocca P, Prigione I, et al. (2012) The E3 ubiquitin ligase TRIM11 mediates the degradation of congenital central hypoventilation syndrome-associated polyalanine-expanded PHOX2B. J Mol Med (Berl) 90: 1025-1035.
41. Sharifi HJ, Furuya AK, Jellinger RM, Nekorchuk MD, de Noronha CM (2014) Cullin 4A and Cullin4B are Interchangeable for HIV Vpr and Vpx Action Through the CRL4 Ubiquitin Ligase Complex. J Virol 88(12): 6944-6958.
42. Nekorchuk MD, Sharifi HJ, Furuya AK, Jellinger R, de Noronha CM (2013) HIV relies on neddylation for ubiquitin ligase-mediated functions. Retrovirology 10: 138.
43. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, et al. (2006) Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349: 300-315. (Pubitemid 43796239)
44. Saraiva Raposo RA, Abdel-Mohsen M, Bilska M, Montefiori D, Nixon DF, et al. (2013) Effects of Cellular Activation on Anti-HIV-1 Restriction Factor Expression Profile in Primary Cells. J Virol 87(21): 11924-11929.
45. Barr SD, Smiley JR, Bushman FD (2008) The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 4: e1000007.
46. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103: 5514-5519.
47. Li X, Kim J, Song B, Finzi A, Pacheco B, et al. (2013) Virus-Specific Effects of TRIM5alpharh RING Domain Functions on Restriction of Retroviruses. J Virol 87: 7234-7245.
48. Okada H, Zhang X, Ben Fofana I, Nagai M, Suzuki H, et al. (2009) Synergistic effect of human CycT1 and CRM1 on HIV-1 propagation in rat T cells and macrophages. Retrovirology 6: 43.
49. de Silva S, Planelles V, Wu L (2012) Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells. PLoS One 7: e35385.
50. Pertel T, Reinhard C, Luban J (2011) Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology 8: 49.